• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Medicines Patent Pool Sublicenses New Antibiotic Candidate To TB Alliance For Development

24/03/2017 by Intellectual Property Watch 2 Comments

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

By Kim Treanor for Intellectual Property Watch

TB Alliance and the Medicines Patent Pool announced today a licensing agreement for the development of sutezolid, a new antibiotic drug candidate which may be used to treat tuberculosis.

TB Alliance is a not-for-profit organisation which works to find affordable medicines to fight tuberculosis. The Medicines Patent Pool (MPP) is a United Nations-backed organisation which works to increase access to HIV, hepatitis C and tuberculosis treatments in low and middle income countries. Medicines Patent Pool was awarded an exclusive licence on the drug candidate from John Hopkins University (US), which holds the patent on the compound. MPP has sublicensed the patent to TB Alliance so that the groups can collaborate in clinical development of the drug.

If effective, sutezolid would be only the third new antibiotic for tuberculosis developed in the last 40 years, the groups said. The disease has the highest mortality rate of any infectious disease, and many of the afflicted have developed resistance to first line treatments. A six month course of treatment for one other antibiotic which was developed recently to treat drug resistant tuberculosis, bedaquiline, brand name Sirturo, has been priced at US$30,000, US$3,000, and US$900 for high, middle and low-income countries, respectively.

While the drugs are effective, their cost and the amount of time necessary to complete a course of treatment have led to criticisms. TB Alliance said it aims to create a new drug regimen for tuberculosis which is effective in a shorter timeframe, accessible and affordable.

[Update:] Separately, UNAIDS said in a release that in 2016, countries set a goal of reducing tuberculosis deaths by 75 percent by the year 2020, as a part of the United Nations Political Declaration on Ending AIDS. UNAIDS has warned that unless urgent action is taken, this target will be missed.

Kim Treanor is an intern at Intellectual Property Watch and a student in the graduate program of International Affairs at the New School in New York, where she studies development, trade and public health.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Medicines Patent Pool Sublicenses New Antibiotic Candidate To TB Alliance For Development" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, WHO

Trackbacks

  1. Links 24/3/2017: Microsoft Aggression, Eudyptula Challenge Status Report | Techrights says:
    25/03/2017 at 1:20 am

    […] Medicines Patent Pool Sublicenses New Antibiotic Candidate To TB Alliance For Development […]

    Reply
  2. Medicines Patent Pool Sublicenses New Antibiotic Candidate To TB Alliance For Development – WebLegal says:
    25/03/2017 at 10:12 am

    […] development of sutezolid, a new antibiotic drug candidate which may be used to treat tuberculosis. Fonte:https://www.ip-watch.org/2017/03/24/medicines-patent-pool-sublicenses-new-antibiotic-candidate… Author: Kim […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2025 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.